it is an an Exploratory Single-Arm, Single-Center Study of Pembrolizumab in Combination with SOX Regimen for Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer
Consistent with high-frequency microsatellite instability MSI-H
Consistent with high tumor mutation load TMB-H (≥10 mutations/megabases)
Hemoglobin ≥90g/L;
Absolute neutrophil count ≥1.5×109/ L;
Patients with severe hypertension and poor drug control;
Patients with difficulty in taking oral drugs due to dysphagia, complete or incomplete digestive tract obstruction, active gastrointestinal bleeding, perforation, etc.;
People who are known to be allergic to the ingredients in the test drug or have metabolic disorders;
Simultaneously participating in other tumor experimental drugs or being in other tumor clinical trials.